IP Library › Granted Patent US 7,338,794
Granted Patent B2
US 7,338,794 · App. 10/681,540 · Granted Mar 4, 2008

Amended recombinant cells for the production and delivery of gamma interferon as an antiviral agent, adjuvant and vaccine accelerant

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,338,794
App. No.
10/681,540
Granted
Mar 4, 2008
Kind
B2
Abstract

The present invention provides active cytokine and/or chemokine compositions, as well as inexpensive means for the production, amended-cell encasement of active cytokine and/or chemokine compositions, processing, and delivery of active cytokine and/or chemokine compositions. The subject invention also provides methods of treatment and methods of accelerating an immune response comprising the administration of amended recombinant cell (ARC) containing cytokine and/or chemokine compositions to animals or humans.

Claims (22)

1. An amended recombinant cell (ARC) comprising at least one heterologous gene, said at least one heterologous gene encoding a chemokine or a cytokine, wherein said amended recombinant cell is Pseudomonas fluorescens.

2. The ARC according to claim 1 , wherein said ARC further comprises at least one additional heterologous gene encodes IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-15, Il-16, Il-18, IL-23, IL-24, erythropoietin, G-CSF, M-CSF, platelet derived growth factor (PDGF), MSF, FLT-3 ligand, EGF, fibroblast growth factor (FGF); aFGF (FGF-1); bFGF (FGF-2); FGF-3; FGF-4; FGF-5; FGF-6; FGF-7; insulin-like growth factor 1 (IGF-1); IGF-2; vascular endothelial growth factor (VEGF); IFN-γ; IFN-α; IFN-β; leukemia inhibitory factor (LIF); ciliary neurotrophic factor (CNTF); oncostatin M; stem cell factor (SCF); TGF-α; TGF-β1; TGFβ2; a chemokine selected from the group consisting of BCA-1/BLC-1, BRAK/Kec, CXCL16, CXCR3, ENA-78/LIX, Eotaxin-1, Eotaxin-2/MPIF-2, Exodus-2/SLC, Fractalkine/Neurotactin, GROalpha/MGSA, HCC-1, I-TAC, Lymphotactin/ATAC/SCM, MCP-1/MCAF, MCP-3, MCP-4, MDC/STCP-1, ABCD-1, MIP-1α, MIP-1β, MIP-2α/GROβ, MIP-3α/Exodus/LARC, MIP-3β/Exodus-3/ELC, MIP-4/PARC/DC-CK1, PF-4, RANTES, SDF1α, TARC, and TECK; or those cytokines or chemokines provided in Tables 1, 8, and 9.

3. The ARC according to claim 1 , wherein said at least one heterologous gene encodes IFN-γ.

4. The ARC according to claim 3 , wherein said IFN-γ is bovine, avian, fish, or human.

5. The ARC according to claim 4 , wherein said IFN-γ is bovine.

6. The ARC according to claim 4 , wherein said avian IFN-γ is chicken IFN-γ.

7. The ARC according to claim 2 , wherein said at least one additional heterologous gene encodes IFN-α.

8. A composition comprising an ARC according to claim 1 and a carrier.

9. A method of inducing or accelerating an immune response in an individual to an antigen or immunogen comprising the step of administering, to an individual:

amended recombinant Pseudomonas fluorescens cells (ARCs) comprising at least one heterologous gene encoding a chemokine or a cytokine; or

a composition comprising amended recombinant Pseudomonas fluorescens cells (ARCs) comprising at least one heterologous gene encoding a chemokine or a cytokine.

10. The method according to claim 9 , wherein said method further comprises the administration of an antigen of interest.

11. The method according to claim 10 , further comprising the administration of lipopolysaceharide (LPS).

12. The method according to claim 9 , wherein said heterologous gene encodes IFN-γ.

13. The method according to claim 12 , wherein said IFN-γ is bovine, avian, fish, or human.

14. The method according to claim 13 , wherein said IFN-γ is bovine.

15. The method according to claim 13 , wherein said avian IFN-γ is chicken IFN-γ.

16. The method according to claim 9 , wherein the ARCs co-express at least one antigen of interest.

17. The ARC according to claim 3 , wherein said ARC further comprises at least one additional heterologous gene that encodes IFN-α.

18. The method according to claim 9 , wherein said ARCs further comprise at least one additional heterologous gene that encodes IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-15, Il-16, Il-18, IL-23, IL-24, erythropoietin, G-CSF, M-CSF, platelet derived growth factor (PDGF), MSF, FLT-3 ligand, EGF, fibroblast growth factor (FGF); aFGF (FGF-1); bFGF (FGF-2); FGF-3; FGF-4; FGF-5; FGF-6; FGF-7; insulin-like growth factor 1 (IGF-1); IGF-2; vascular endothelial growth factor (VEGF); IFN-γ; IFN-α; IFN-β; leukemia inhibitory factor (LIF); ciliary neurotrophic factor (CNTF); oncostatin M; stem cell factor (SCF); TGF-α; TGF-β1; TGF-β2; a chemokine selected from the group consisting of BCA-1/BLC-1, BRAK/Kec, CXCL16, CXCR3, ENA-78/LIX, Eotaxin-1, Eotaxin-2/MPIF-2, Exodus-2/SLC, Fractalkine/Neurotactin, GROalpha/MGSA, HCC-1, I-TAC, Lymphotactin/ATAC/SCM, MCP-1/MCAF, MCP-3, MCP-4, MDC/STCP-1, ABCD-1, MIP-1α, MIP-1β, MIP-2α/GROβ, MIP-3α/Exodus/LARC, MIP-3β/Exodus-3/ELC, MIP-4/PARC/DC-CK1, PF-4, RANTES, SDF1α, TARC, and TECK; or a cytokine or chemokine as provided in Tables 1, 8, and 9.

19. The method according to claim 18 , wherein said at least one additional heterologous gene encodes IFN-α.

20. The method according to claim 12 , wherein said ARCs further comprise at least one additional heterologous gene that encodes IFN-α.

Assignments (2)
CHANGE OF NAME Recorded Nov 8, 2021
From: DOW AGROSCIENCES LLC
To: CORTEVA AGRISCIENCE LLC
Reel/Frame 058044/0184 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 9, 2004
From: GAERTNER, FRANK H.; LEE, STACEY LYNN; SHUTTER, ROBERT
To: DOW AGROSCIENCES LLC
Reel/Frame 014507/0878 →